• Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise

Log in

Start free trial
G2 Intelligence
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
FDA Approves Teal Wand as First At-Home Cervical Cancer Screening

FDA Approves Teal Wand as First At-Home Cervical Cancer Screening

by Ron Shinkman | Jun 27, 2025 | Clinical Diagnostics Insider, DTC-dtet, Emerging Tests-dtet, FDA-dtet, Testing Trends-dtet

Teal Health, the company manufacturing and distributing the test, says thousands of women are already on a waiting list for the assay

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
MeMed Sepsis Test Gains Breakthrough Device Designation

MeMed Sepsis Test Gains Breakthrough Device Designation

by Ron Shinkman | Jan 31, 2025 | Essential, FDA-lca, Lab Industry Advisor

The 15-minute assay to detect sepsis and assess its severity and risk is expected to get full FDA approval by 2026

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Implementing Accessible On-Demand Testing: A Lab Director’s Experience

Implementing Accessible On-Demand Testing: A Lab Director’s Experience

by Christina (Christy) Nickel, MHA, MLS(ASCP)CM, CPHQ | Jan 28, 2025 | Clinical Diagnostics Insider, DTC-dtet

On-demand testing doesn’t require registration, billing, or scheduling, keeping costs low while collecting “real” dollars upfront

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Dx Deals: Could Health Coaching Be a New Opportunity for Labs?

Dx Deals: Could Health Coaching Be a New Opportunity for Labs?

by Ron Shinkman | Jan 24, 2025 | Deals-lir, Essential, Lab Industry Advisor

Quest Diagnostics will find out as it launches a new health coaching business that relies on lab testing, via its Pack Health subsidiary

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Patients at the Point of Care

Patients at the Point of Care

by Michael Schubert, PhD | Jan 20, 2025 | Clinical Diagnostics Insider, DTC-dtet, Point of Care-dtet, Testing Trends-dtet

At-home testing is giving patients an increasingly active role in managing their health—but what does this trend mean for labs?

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
« Older Entries

Log In

Join Now | Lost Password?
  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
Copyright © 2025 G2Intelligence.com